Jessica A. O. Zimmerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessica A. O. Zimmerman has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- David J. Gordon
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa
19 shared publications - Dawn E. Quelle
Cancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA
19 shared publications - Elizabeth L. Geary
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
19 shared publications - Emma E. Croushore
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
19 shared publications - Jenna M. Gedminas
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
19 shared publications - Mary V. Thomas
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
19 shared publications
Latest Publications
- 1 August 2026
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 141 (2) , 494-501
Anthracycline chemotherapy does not increase arterial stiffness or carotid intima-media thickness in young adult survivors of hematological malignancies
Cancer survivors treated with anthracycline chemotherapy have increased risk for cardiovascular disease in later life. Findings from the present study show that arterial stiffness is not elevated among individuals post anthracycline chemotherapy, suggesting that large artery stiffness does not contribute to the increased cardiovascular risk observed in this population.
- 1 August 2026
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 141 (2) , 494-501
Anthracycline chemotherapy does not increase arterial stiffness or carotid intima-media thickness in young adult survivors of hematological malignancies
Cancer survivors treated with anthracycline chemotherapy have increased risk for cardiovascular disease in later life. Findings from the present study show that arterial stiffness is not elevated among individuals post anthracycline chemotherapy, suggesting that large artery stiffness does not contribute to the increased cardiovascular risk observed in this population.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors downregulate the expression of genes related to DNA replication and the cellular response to DNA replication stress. A, EW8 cells were treated with panobinostat or romidepsin for 24 hours, and then cellular lysates and mRNA were collected for immunoblotting and RNA-seq analysis. B and C, Volcano plots of differentially expressed genes (fold change >2, adjusted P value < 0.05) in the EW8 cells treated with romidepsin (5 nmol/L; B) or panobinostat (10 nmol/L; C). D–E, RNA-seq data, fold change and adjusted P value, for the RRM1, RRM2, CHK1, and WEE1 genes in EW8 cells treated with romidepsin (5 nmol/L) and panobinostat (10 nmol/L). F and G, Gene sets (Kyoto Encyclopedia of Genes and Genomes pathway) enriched in the genes that are downregulated in EW8 cells treated with romidepsin (F) and panobinostat (G). H, RNA-seq data, fold change and adjusted P value, for the MCM2–7 genes in EW8 cells treated with romidepsin and panobinostat. I, EW8 and TC71 cells were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors downregulate the expression of genes related to DNA replication and the cellular response to DNA replication stress. A, EW8 cells were treated with panobinostat or romidepsin for 24 hours, and then cellular lysates and mRNA were collected for immunoblotting and RNA-seq analysis. B and C, Volcano plots of differentially expressed genes (fold change >2, adjusted P value < 0.05) in the EW8 cells treated with romidepsin (5 nmol/L; B) or panobinostat (10 nmol/L; C). D–E, RNA-seq data, fold change and adjusted P value, for the RRM1, RRM2, CHK1, and WEE1 genes in EW8 cells treated with romidepsin (5 nmol/L) and panobinostat (10 nmol/L). F and G, Gene sets (Kyoto Encyclopedia of Genes and Genomes pathway) enriched in the genes that are downregulated in EW8 cells treated with romidepsin (F) and panobinostat (G). H, RNA-seq data, fold change and adjusted P value, for the MCM2–7 genes in EW8 cells treated with romidepsin and panobinostat. I, EW8 and TC71 cells were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors upregulate and downregulate genes that are regulated by EWS::FLI1. A and B, Results of transcription factor enrichment analysis performed with the genes that are upregulated (A) and downregulated (B) in EW8 cells treated with romidepsin. C and D, Overlap between genes upregulated (C) and downregulated (D) in EW8 cells treated with romidepsin or siEWS::FLI1. E, Relative EWS::FLI1 mRNA in EW8 and TC71 cells treated with romidepsin for 24 hours. F, EW8 and TC71 cells were treated with romidepsin or panobinostat for 24 hours, and then cellular lysates were collected for immunoblotting for the EWS::FLI1 oncoprotein.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors upregulate and downregulate genes that are regulated by EWS::FLI1. A and B, Results of transcription factor enrichment analysis performed with the genes that are upregulated (A) and downregulated (B) in EW8 cells treated with romidepsin. C and D, Overlap between genes upregulated (C) and downregulated (D) in EW8 cells treated with romidepsin or siEWS::FLI1. E, Relative EWS::FLI1 mRNA in EW8 and TC71 cells treated with romidepsin for 24 hours. F, EW8 and TC71 cells were treated with romidepsin or panobinostat for 24 hours, and then cellular lysates were collected for immunoblotting for the EWS::FLI1 oncoprotein.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Effects of romidepsin and panobinostat on protein expression levels.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Effects of romidepsin and panobinostat on protein expression levels.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Romidepsin and panobinostat inhibit the growth of Ewing sarcoma cells.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Romidepsin and panobinostat inhibit the growth of Ewing sarcoma cells.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with YM155 for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors downregulate survivin (BIRC5) in Ewing sarcoma cells. A, Treatment with romidepsin (5 nmol/L) causes morphologic changes in Ewing sarcoma cells. B, EW8 and TC71 cells were treated with romidepsin for 24 or 30 hours, and then cellular lysates were collected for immunoblotting. C, RNA-seq data, fold change and adjusted P value, for the survivin gene in EW8 cells treated with romidepsin and panobinostat. D, Ewing sarcoma cell lines were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. E, Survivin mRNA expression level and CRISPR dependency score in Ewing sarcoma, other sarcoma, and other cancer cell lines. F, EW8 and TC71 cells were treated with YM155 for 24 hours, and then cellular lysates were collected for immunoblotting for survivin. G, EW8 cells were treated with different doses of YM115 for 72 hours, and then cell viability was measured using the alamarBlue assay. Error bars represent the mean ± SD of three technical replicates. The results are representative of two independent experiments. H, Kaplan–Meier analysis shows the overall survival of patients with Ewing sarcoma according to the expression level of survivin mRNA. P values were calculated using a one-way ANOVA followed by the Dunnett multiple comparisons test. TPM, transcripts per million. ***, P < 0.001.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Kaplan-Meier analysis shows overall survival of patients with Ewing sarcoma tumors according to expression level of MCM3-7 mRNA.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Kaplan-Meier analysis shows overall survival of patients with Ewing sarcoma tumors according to expression level of MCM3-7 mRNA.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors decrease BRD4 protein levels in Ewing sarcoma cells. A and B, Comparison of protein expression, based on RPPAs, in EW8 (A) or TC71 (B) cells treated with romidepsin (5 nmol/L) or panobinostat (10 nmol/L) for 24 hours. C, Overlap of proteins downregulated >1.5-fold in the RPPA experiment by romidepsin and panobinostat in Ewing sarcoma (ES6, EW8, and TC71) and osteosarcoma (U2OS) cell lines. D, Relative BRD4 mRNA in EW8 and TC71 cells treated with romidepsin (5 nmol/L). E, EW8 and TC71 cells were treated with romidepsin or panobinostat for 24 hours, and then cellular lysates were collected for immunoblotting for BRD4. F, CRISPR and shRNA dependency scores for BRD4 (Dependency Map, Broad Institute) in Ewing sarcoma and other cancer cell lines. G, EW8 and TC71 cells were treated with dBET1 (5 μmol/L) for 18 hours, and then cellular lysates were collected for immunoblotting for BRD4. H, Representative cell-cycle analysis (EdU and propidium iodide) plot for EW8 cells treated with dBET1 (5 µmol/L) for 18 hours. I, Summary of EdU incorporation into DNA for additional Ewing sarcoma cell lines treated with dBET1 (5 µmol/L) for 18 hours. P values were calculated using a two-tailed Student t test. **, P < 0.01. FC, fold change.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
HDAC inhibitors decrease BRD4 protein levels in Ewing sarcoma cells. A and B, Comparison of protein expression, based on RPPAs, in EW8 (A) or TC71 (B) cells treated with romidepsin (5 nmol/L) or panobinostat (10 nmol/L) for 24 hours. C, Overlap of proteins downregulated >1.5-fold in the RPPA experiment by romidepsin and panobinostat in Ewing sarcoma (ES6, EW8, and TC71) and osteosarcoma (U2OS) cell lines. D, Relative BRD4 mRNA in EW8 and TC71 cells treated with romidepsin (5 nmol/L). E, EW8 and TC71 cells were treated with romidepsin or panobinostat for 24 hours, and then cellular lysates were collected for immunoblotting for BRD4. F, CRISPR and shRNA dependency scores for BRD4 (Dependency Map, Broad Institute) in Ewing sarcoma and other cancer cell lines. G, EW8 and TC71 cells were treated with dBET1 (5 μmol/L) for 18 hours, and then cellular lysates were collected for immunoblotting for BRD4. H, Representative cell-cycle analysis (EdU and propidium iodide) plot for EW8 cells treated with dBET1 (5 µmol/L) for 18 hours. I, Summary of EdU incorporation into DNA for additional Ewing sarcoma cell lines treated with dBET1 (5 µmol/L) for 18 hours. P values were calculated using a two-tailed Student t test. **, P < 0.01. FC, fold change.
- Open Access
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase, and the ATR–checkpoint kinase 1 (CHK1)–WEE1 signaling pathway. In this study, we identified that multiple HDAC inhibitors, including fimepinostat, romidepsin, and panobinostat, downregulate the levels of the RRM1, RRM2, CHK1, and WEE1 proteins in Ewing sarcoma cells and impair DNA replication. Moreover, transcriptome analyses identified that HDAC inhibitors downregulate the expression of multiple components of the prereplication complex, including the minichromosome maintenance complex 2–7 (MCM2–7) proteins and CDT1, that are essential for genomic DNA replication. Additionally, proteomic studies identified that HDAC inhibitors also downregulate the level of the BRD4 protein, a BET bromodomain protein that regulates both the transcriptional program of the EWS::FLI1 oncoprotein and DNA replication. Overall, these results provide novel insight into the molecular mechanisms by which HDAC inhibitors target cancer cells, regulate DNA replication, and inhibit the cellular response to DNA replication stress.Significance:In this work, we identify that HDAC inhibitors broadly disrupt DNA replication and the response to replication stress in Ewing sarcoma cells by downregulating RRM1, RRM2, CHK1, and WEE1. Notably, HDAC inhibitors also reduce MCM2–7 proteins, which are essential for prereplication complex helicase function in replication initiation and elongation, and CDT1, which loads MCM2–7 onto DNA.
- 27 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase, and the ATR–checkpoint kinase 1 (CHK1)–WEE1 signaling pathway. In this study, we identified that multiple HDAC inhibitors, including fimepinostat, romidepsin, and panobinostat, downregulate the levels of the RRM1, RRM2, CHK1, and WEE1 proteins in Ewing sarcoma cells and impair DNA replication. Moreover, transcriptome analyses identified that HDAC inhibitors downregulate the expression of multiple components of the prereplication complex, including the minichromosome maintenance complex 2–7 (MCM2–7) proteins and CDT1, that are essential for genomic DNA replication. Additionally, proteomic studies identified that HDAC inhibitors also downregulate the level of the BRD4 protein, a BET bromodomain protein that regulates both the transcriptional program of the EWS::FLI1 oncoprotein and DNA replication. Overall, these results provide novel insight into the molecular mechanisms by which HDAC inhibitors target cancer cells, regulate DNA replication, and inhibit the cellular response to DNA replication stress.Significance:In this work, we identify that HDAC inhibitors broadly disrupt DNA replication and the response to replication stress in Ewing sarcoma cells by downregulating RRM1, RRM2, CHK1, and WEE1. Notably, HDAC inhibitors also reduce MCM2–7 proteins, which are essential for prereplication complex helicase function in replication initiation and elongation, and CDT1, which loads MCM2–7 onto DNA.